A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Phase 1
NK Cell
IL13Ra
EGFRvIII
Chimera Antigen Receptor (CAR)
NR3C1
Recurrent Glioblastoma

Interventions

DRUG: NK Cells
DRUG: NK Cells

Sponsor

M.D. Anderson Cancer Center